|Table of Contents|

Advances of antibody drug conjugate for acute myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
1062-1068
Research Field:
Publishing date:

Info

Title:
Advances of antibody drug conjugate for acute myeloid leukemia
Author(s):
WANG Yujiao1; YANG Jincai1; ZHAO Li2
1.The First School of Clinical Medicine,Lanzhou University，Gansu Lanzhou 730000，China；2.Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases，Gansu Lanzhou 730000，China.
Keywords:
acute myeloid leukemia; immunotargeted therapy; antibody drug conjugate
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2025.06.026
Abstract:
Acute myeloid leukemia (AML) is among the most prevalent types of leukemia in adults,and its primary treatment modality involves conventional chemotherapy.Despite the high complete remission rate (CRR) associated with standard chemotherapy regimens,the propensity for relapse and drug resistance contributes to a poor prognosis for patients.Consequently,there is an urgent need for safer and more effective therapeutic approaches to enhance patient survival rate.Antibody drug conjugates (ADC),which represent a novel class of immune-targeted therapeutic agents that combine monoclonal antibodies with cytotoxic drugs,offer a highly efficient and specific treatment option that may present new strategies for managing AML.Several ADC targeting AML have already been employed in clinical treatment,with many still undergoing clinical trials.This review provides an overview of the research progress on ADC in the context of AML treatment.

References:

［1］DINARDO CD,ERBA HP,FREEMAN SD,et al.Acute myeloid leukaemia［J］.The Lancet,2023,401(10393):2073-2086.
［2］DOHNER H,WEI AH,APPELBAUM FR,et al.Diagnosis and management of AML in adults:2022 recommendations from an international expert panel on behalf of the ELN［J］.Blood,2022,140(12):1345-1377.
［3］AURELI A,MARZIANI B,SCONOCCHIA T,et al.Immunotherapy as a turning point in the treatment of acute myeloid leukemia［J］.Cancers,2021,13(24):6246.
［4］Leukemia & Lymphoma Group,Chinese Society of Hematology,Chinese Medical Association.Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia(not APL)(2023)［J］.Chinese Journal of Hematology,2023,44(9):705-712.
［5］UDDIN R,DARWISH NHE,MOUSA SA.Acute myeloid leukemia mutations and future mechanistic target to overcome resistance［J］.Current Treatment Options in Oncology,2021,22(9):76.
［6］WANG J,TOMLINSON B,LAZARUS HM.Update on small molecule targeted therapies for acute myeloid leukemia［J］.Current Treatment Options in Oncology,2023,24(7):770-801.
［7］WU Y,LI Y,GAO Y,et al.Immunotherapies of acute myeloid leukemia:Rationale,clinical evidence and perspective［J］.Biomedicine & Pharmacotherapy,2024,171:116132.
［8］MAHMOOD I.Clinical pharmacology of antibody-drug conjugates［J］.Antibodies,2021,10(2):20.
［9］KUMARI S,RAJ S,BABU MA,et al.Antibody-drug conjugates in cancer therapy:innovations,challenges,and future directions［J］.Archives of Pharmacal Research,2024,47(1):40-65.
［10］KHONGORZUL P,LING CJ,KHAN FU,et al.Antibody-drug conjugates:A comprehensive review［J］.Molecular Cancer Research,2020,18(1):3-19.
［11］DRAGO JZ,MODI S,CHANDARLAPATY S.Unlocking the potential of antibody-drug conjugates for cancer therapy［J］.Nature Reviews Clinical Oncology,2021,18(6):327-344.
［12］JIN YM,SCHLADETSCH MA,HUANG XT,et al.Stepping forward in antibody-drug conjugate development［J］.Pharmacology & Therapeutics,2022,229:107917.
［13］LIANG Y,ZHANG PR,LI F,et al.Advances in the study of marketed antibody-drug conjugates (ADCs) for the treatment of breast cancer［J］.Frontiers in Pharmacology,2024,14:1332539.
［14］FU Z,LI S,HAN S,et al.Antibody drug conjugate:the "biological missile" for targeted cancer therapy［J］.Signal Transduction and Targeted Therapy,2022,7(1):93.
［15］MAAKARON JE,ROGOSHESKE J,LONG MX,et al.CD33-targeted therapies:Beating the disease or beaten to death［J］.The Journal of Clinical Pharmacology,2021,61(1):7-17.
［16］SENAPATI J,DAVER NG,PEMMARAJU N.Antibody-drug conjugates in myeloid leukemias［J］.The Cancer Journal,2022,28(6):454-461.
［17］LAMBERT J,PAUTAS C,TERRE C,et al.Gemtuzumab ozogamicin for de novo acute myeloid leukemia:final efficacy and safety updates from the open-label,phase Ⅲ ALFA-0701 trial［J］.Haematologica,2019,104(1):113-119.
［18］RUSSELL NH,WILHELM-BENARTZI C,OTHMAN J,et al.Fludarabine,cytarabine,granulocyte colony-stimulating factor,and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with NPM1 and FLT3 mutations［J］.Journal of Clinical Oncology,2024,42(10):1158-1168.
［19］SATOMAA T,PYNNONEN H,AITIO O,et al.Targeting CD33+ acute myeloid leukemia with GLK-33,a lintuzumab-auristatin conjugate with a wide therapeutic window［J］.Molecular Cancer Therapeutics,2024,23(8):1073-1083.
［20］AHCI HE,DUPONT E,PAUL S,et al.CD123 as a biomarker in hematolymphoid malignancies:Principles of detection and targeted therapies［J］.Cancers,2020,12(11):3087.
［21］PELOSI E,CASTELLI G,TESTA U.CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm［J］.International Journal of Molecular Sciences,2023,24(3):2718.
［22］DAVER NG,MONTESINOS P,DEANGELO DJ,et al.Pivekimab sunirine (IMGN632),a novel CD123-targeting antibody-drug conjugate,in relapsed or refractory acute myeloid leukaemia:a phase 1/2 study［J］.The Lancet Oncology,2024,25(3):388-399.
［23］DAVER N,MONTESINOS P,ARIBI A,et al.Pivekimab sunirine (PVEK,IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and reduced infusion-related reactions［C］//Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting,2022,22:S231-S232.
［24］BRUZZESE A,MARTINO EA,LABANCA C,et al.Tagraxofusp in myeloid malignancies［J］.Hematological Oncology,2024,42(1):e3234.
［25］LANE AA,SWEET KL,WANG ES,et al.Results from ongoing phase 1/2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with minimal residual disease (MRD)［J］.Blood,2017,130:2583.
［26］MINETTO P,ROSELLINI S,GUOLO F,et al.Single agent tagraxofusp in relapsed/refractory CD123-positive acute myeloid leukemia:A preliminary analysis of Italian Gimema AML2020 trial［J］.Blood,2023,142:2918.
［27］LANE AA,GARCIA JS,RAULSTON EG,et al.Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia［J］.Blood Advances,2024,8(3):591-602.
［28］HAN L,JORGENSEN JL,BROOKS C,et al.Antileukemia efficacy and mechanisms of action of SL-101,a novel anti-CD123 antibody conjugate,in acute myeloid leukemia［J］.Clinical Cancer Research,2017,23(13):3385-3395.
［29］MARCUCCI F,CASERTA CA,ROMEO E,et al.Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC)-is there still room for optimism［J］.Frontiers in Oncology,2019,9:167.
［30］FANG Z,FU J,CHEN X.A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia［J］.Hematology,2024,29(1):2300855.
［31］PEREIRA DS,GUEVARA CI,JIN L,et al.AGS67E,an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML:A new role for CD37 in AML［J］.Molecular Cancer Therapeutics,2015,14(7):1650-1660.
［32］STEINSLAND THDD,GULLAKSEN SE,BREDHOLT G,et al.The transmembrane protein CD37 is not a promising therapeutic target in acute myeloid leukaemia［J］.Blood,2020,136:26.
［33］WANG X,ZHANG Y,XUE S.Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia［J］.Annals of Hematology,2024,103(6):1843-1857.
［34］ABDEL-AZIZ AK,DOKLA EME,SAADELDIN MK.FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance:An updated comprehensive review［J］.Critical Reviews in Oncology/Hematology,2023,191:104139.
［35］SNYDER JT,MALINAO MC,DUGAL-TESSIER J,et al.Metabolism of an oxime-linked antibody drug conjugate,AGS62P1,and characterization of its identified metabolite［J］.Molecular Pharmaceutics,2018,15(6):2384-2390.
［36］ROAS M,VICK B,KASPER MA,et al.Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML［J］.Blood,2023,141(9):1023-1035.
［37］RUDRA-GANGULY N,LOWE C,VIRATA C,et al.AGS62P1,a novel anti-FLT3 antibody drug conjugate,employing site specific conjugation,demonstrates preclinical anti-tumor efficacy in AML tumor and patient derived xenografts［J］.Blood,2015,126(23):3806.
［38］ABAZA Y,FATHI AT.Monoclonal antibodies in acute myeloid leukemia-are we there yet［J］.The Cancer Journal,2022,28(1):37-42.
［39］YANAGISAWA B,PERKINS B,KARANTANOS T,et al.Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes［J］.Leukemia Research,2020,99:106477.
［40］XIE X,ZHANG W,ZHOU X,et al.Low doses of IFN-γ maintain self-renewal of leukemia stem cells in acute myeloid leukemia［J］.Oncogene,2023,42(50):3657-3669.
［41］JIANG YP,LIU BY,ZHENG Q,et al.CLT030,a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia［J］.Blood Advances,2018,2(14):1738-1749.
［42］ZHENG B,YU SF,ROSARIO GD,et al.An anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia［J］.Clinical Cancer Research,2019,25(4):1358-1368.
［43］DAVER N,SALHOTRA A,BRANDWEIN JM,et al.A phase Ⅰ dose-escalation study of DCLL9718S,an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia［J］.American Journal of Hematology,2021,96(5):E175-E179.
［44］ZHU Y,LIU K,WANG K,et al.Treatment-related adverse events of antibody-drug conjugates in clinical trials:A systematic review and meta-analysis［J］.Cancer,2023,129(2):283-295.
［45］ENDO Y,MOHAN N,DOKMANOVIC M,et al.Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities:a gateway to better understanding of ADC-associated toxicities［J］.Antibody Therapeutics,2021,4(1):55-59.

Memo

Memo:
-
Last Update: 1900-01-01